Skip to main content
OpenTrials
Completed

NCT Number: NCT02052531

Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus

The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific Corporation in patients with dermal pruritus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Kyu-Han Kim

Seoul, 110-744, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients at the age of 20 to 65 years old (both inclusive)
  • Pruritus test ≥ 5cm (10cm Visual Analogue Scale [VAS]) at baseline
  • Eczema or dry skin on the study drug application site
  • Women of childbearing potential should have a negative urine pregnancy test at screening and agree to employ an effective method of birth control (surgical sterilization or oral contraceptives, barrier method with spermicides, intrauterine device, etc.) during the study period.
  • Voluntarily signed written informed consent forms for study participation.

Exclusion criteria

  • Pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.
  • Chronic skin diseases such as malignant tumor or chronic urticaria, among skin diseases.
  • Simple pruritus caused by allergic substances such as scabies or insect bites.
  • Presence of symptoms of generalized infection at the time of study participation.
  • Previous local treatment or antibiotics administration for pruritus within 7 days prior to study participation.
  • Previous use of oral steroids within 1 month and local steroids within 2 weeks prior to study participation.
  • History of physical treatment for pruritus, including phototherapy, within 1 month prior to study participation.
  • Patients who are treated with prohibited concomitant drugs or considered to inevitably require treatment with prohibited concomitant drugs during the study period.
  • Renal function impairment with creatinine level
  • Hepatic function impairment with aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)
  • Pregnant and lactating women
  • Participation in another clinical study within 1 month prior to screening.
  • Patients considered ineligible for study participation by the principal investigator or sub-investigator for other reasons; pruritus due to other medical (liver disease, renal failure, etc.), psychotic, or neuropathic causes rather than as a skin disease.

Treatment and study plan

PAC-14028

Drug

Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks

Other names: PAC-14028 Cream 0.3%, PAC-14028 Cream 1.0%

Vehicle

Other

Participants received topical Vehicle twice daily for 4 weeks

Other names: Vehicle of PAC-14028 Cream

Primary outcomes

  1. Change in Visual Analog Scale (VAS)

    Time frame: Baseline through Study Day 28

    Patient reported outcome of pruritis measurement on a change in visual analog scale

Secondary outcomes

  1. Treatment success rate

    Time frame: Baseline through Study Day 28

  2. Change in specified symptom sum score (SRRC) Index

    Time frame: Baseline through Study Day 28

  3. Change in transepidermal water loss

    Time frame: Baseline through Study Day 28

  4. Change in skin hydration

    Time frame: Baseline through Study Day 28

Sponsors and collaborators

Lead sponsor

Amorepacific Corporation

Industry

Registry information

Official study title

A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Feb 3, 2014
Registry last updated
Sep 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.